tbuckley/cabot-search huggingface dataset:
Mapping<i>Plasmodium falciparum</i>Mortality in Africa between 1990 and 2015
Authors: Peter W. Gething, Daniel C. Casey, Daniel J. Weiss, Donal Bisanzio, Samir Bhatt, Ewan Cameron, Katherine E. Battle, Ursula Dalrymple, Jennifer Rozier, Puja C. Rao, Michael J. Kutz, Ryan M. Barber, Chantal Huynh, Katya A. Shackelford, Matthew M. Coates, Grant Nguyen, Maya S. Fraser, Rachel Kulikoff, Haidong Wang, Mohsen Naghavi, David L. Smith, Christopher J.L. Murray, Simon I. Hay, Stephen S. Lim
Journal: New England Journal of Medicine (2016)

Malaria control has not been routinely informed by the assessment of subnational variation in malaria deaths. We combined data from the Malaria Atlas Project and the Global Burden of Disease Study to estimate malaria mortality across sub-Saharan Africa on a grid of 5 km2 from 1990 through 2015.We estimated malaria mortality using a spatiotemporal modeling framework of geolocated data (i.e., with known latitude and longitude) on the clinical incidence of malaria, coverage of antimalarial drug treatment, case fatality rate, and population distribution according to age.Across sub-Saharan Africa during the past 15 years, we estimated that there was an overall decrease of 57% (95% uncertainty interval, 46 to 65) in the rate of malaria deaths, from 12.5 (95% uncertainty interval, 8.3 to 17.0) per 10,000 population in 2000 to 5.4 (95% uncertainty interval, 3.4 to 7.9) in 2015. This led to an overall decrease of 37% (95% uncertainty interval, 36 to 39) in the number of malaria deaths annually, from 1,007,000 (95% uncertainty interval, 666,000 to 1,376,000) to 631,000 (95% uncertainty interval, 394,000 to 914,000). The share of malaria deaths among children younger than 5 years of age ranged from more than 80% at a rate of death of more than 25 per 10,000 to less than 40% at rates below 1 per 10,000. Areas with high malaria mortality (>10 per 10,000) and low coverage (<50%) of insecticide-treated bed nets and antimalarial drugs included much of Nigeria, Angola, and Cameroon and parts of the Central African Republic, Congo, Guinea, and Equatorial Guinea.We estimated that there was an overall decrease of 57% in the rate of death from malaria across sub-Saharan Africa over the past 15 years and identified several countries in which high rates of death were associated with low coverage of antimalarial treatment and prevention programs. (Funded by the Bill and Melinda Gates Foundation and others.).
MabThera (Rituximab) Plus Cyclophosphamide, Vincristine and Prednisone (CVP) Chemotherapy Improves Survival in Previously Untreated Patients with Advanced Follicular Non-Hodgkin’s Lymphoma (NHL).
Authors: Robert E. Marcus, Philippe Solal-Celigny, Kevin Imrie, John V. Catalano, Anna Dmoszynska, João C. Raposo, Fritz C. Offner, José Gomez-Codina
Journal: Blood (2006)
Effects of a culturally adapted lifestyle intervention on cardio-metabolic outcomes: a randomized controlled trial in Iraqi immigrants to Sweden at high risk for Type 2 diabetes
Authors: Faiza Siddiqui, Azra Kurbasic, Ulf Lindblad, Peter M. Nilsson, Louise Bennet
Journal: Metabolism (2016)

Middle-Eastern immigrants constitute a growing proportion of the Swedish population and are at high risk for Type 2 diabetes. This calls for a more proactive preventive approach for dealing with diabetes risk in this target group. The aim was to test the effect of a culturally adapted lifestyle intervention programme on changes in lifestyle habits and cardio-metabolic outcomes comparing an intervention group with a control group receiving usual care.Citizens of Malmö, Sweden born in Iraq and at high risk for Type 2 diabetes (n=636) were invited. Participation rate was 15.1%. In all, 96 participants were randomized to the intervention group (n=50) or to the control group (n=46). The intervention group was offered seven group sessions addressing healthy diet and physical activity including one cooking class. Changes in body weight, physical activity levels and cardio-metabolic outcomes were evaluated using linear mixed-effects models.The mean follow-up time was 3.9 and 3.5months in the intervention and control groups, respectively. The drop-out rate from baseline to the last visit was 30.0% in the intervention group (n=15) and 30.4% in the control group (n=14). The mean insulin sensitivity index increased significantly at follow-up in the intervention group compared to the control group (10.9% per month, p=0.005). The intervention group also reached a significant reduction in body weight (0.4% per month, p=0.004), body mass index (0.4% per month, p=0.004) and LDL-cholesterol (2.1% per month, p=0.036) compared to the control group. In total, 14.3% in the intervention group reached the goal to lose ≥5% of body weight versus none in the control group.This culturally adapted lifestyle intervention programme shows a beneficial effect on insulin action, body weight reduction, as well as LDL-cholesterol reduction, in Middle-Eastern immigrants. The programme adapted to resources in primary health care provides tools for improved primary prevention and reduced cardio-metabolic risk in this high-risk group for Type 2 diabetes.
Effectiveness of screening colonoscopy in reducing the risk of death from right and left colon cancer: a large community-based study
Authors: Chyke A Doubeni, Douglas A Corley, Virginia P Quinn, Christopher D Jensen, Ann G Zauber, Michael Goodman, Jill R Johnson, Shivan J Mehta, Tracy A Becerra, Wei K Zhao, Joanne Schottinger, V Paul Doria-Rose, Theodore R Levin, Noel S Weiss, Robert H Fletcher
Journal: Gut (2016)

Screening colonoscopy's effectiveness in reducing colorectal cancer mortality risk in community populations is unclear, particularly for right-colon cancers, leading to recommendations against its use for screening in some countries. This study aimed to determine whether, among average-risk people, receipt of screening colonoscopy reduces the risk of dying from both right-colon and left-colon/rectal cancers.We conducted a nested case-control study with incidence-density matching in screening-eligible Kaiser Permanente members. Patients who were 55-90 years old on their colorectal cancer death date during 2006-2012 were matched on diagnosis (reference) date to controls on age, sex, health plan enrolment duration and geographical region. We excluded patients at increased colorectal cancer risk, or with prior colorectal cancer diagnosis or colectomy. The association between screening colonoscopy receipt in the 10-year period before the reference date and colorectal cancer death risk was evaluated while accounting for other screening exposures.We analysed 1747 patients who died from colorectal cancer and 3460 colorectal cancer-free controls. Compared with no endoscopic screening, receipt of a screening colonoscopy was associated with a 67% reduction in the risk of death from any colorectal cancer (adjusted OR (aOR)=0.33, 95% CI 0.21 to 0.52). By cancer location, screening colonoscopy was associated with a 65% reduction in risk of death for right-colon cancers (aOR=0.35, CI 0.18 to 0.65) and a 75% reduction for left-colon/rectal cancers (aOR=0.25, CI 0.12 to 0.53).Screening colonoscopy was associated with a substantial and comparably decreased mortality risk for both right-sided and left-sided cancers within a large community-based population.
TCT-11 Five-year Follow up of the First in Man use of a Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis; A Serial Multi-Imaging Modality Study
Authors: Patrick W. Serruys, Yoshinobu Onuma, Robert J. Van Geuns, Bernard De Bruyne, Dariusz Dudek, Evald H. Christiansen, Bernard Chevalier, Pieter C. Smits, Dougal McCLean, Jacques Koolen, Stephan Windecker, Robert J. Whitbourn, Ian T. Meredith, Luc Wasungu, Divine E. Ediebah, Susan Veldhof, John A. Ormiston
Journal: Journal of the American College of Cardiology (2015)
Lenalidomide Overcomes FcγRIIIa-Mediated Resistance to Rituximab In Patients with Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (NHL): A Correlative Analysis of a Phase 2 Study
Authors: Mrinal Dutia, Ian DeRoock, Christine Reed-Pease, Joseph Tuscano
Journal: Blood (2010)
TCT-667 Aortic Valve Intervention In Octogenarians In The “TAVI-Era”: Analysis Of The UK National Adult Cardiac Surgery Audit Registry And The UK Transcatheter Aortic Valve Implantation (TAVI) Registry between 2006 and 2012
Authors: Neil Moat, Alison Duncan, Simon V. Stephens, Graeme L. Hickey, David Cunningham, Mark de Belder, Daniel J. Blackman, David Hildick-Smith, Ben Bridgewater, Peter Ludman
Journal: Journal of the American College of Cardiology (2015)
The double life of cardiac mesenchymal cells: Epimetabolic sensors and therapeutic assets for heart regeneration
Authors: Chiara Cencioni, Sandra Atlante, Matteo Savoia, Fabio Martelli, Antonella Farsetti, Maurizio C. Capogrossi, Andreas M. Zeiher, Carlo Gaetano, Francesco Spallotta
Journal: Pharmacology & Therapeutics (2016)
Cost-effectiveness of Universal and Targeted Newborn Screening for Congenital Cytomegalovirus Infection
Authors: Soren Gantt, Francois Dionne, Fred K. Kozak, Oran Goshen, David M. Goldfarb, Albert H. Park, Suresh B. Boppana, Karen Fowler
Journal: JAMA Pediatrics (2016)

Congenital cytomegalovirus (cCMV) infection is a major cause of childhood deafness. Most cCMV infections are not diagnosed without newborn screening, resulting in missed opportunities for directed care.To estimate the cost-effectiveness of universal and targeted newborn cCMV screening programs compared with no cCMV screening.Models were constructed using rates and outcomes from prospective cohort studies of newborn cCMV screening in US postpartum care and early hearing programs. Costs of laboratory testing, treatment, and hearing loss were drawn from Medicaid data and published estimates. The benefits of cCMV screening were assumed to come from antiviral therapy for affected newborns to reduce hearing loss and from earlier identification of hearing loss with postnatal onset. Analyses were performed from July 2014 to March 2016.Models compared universal or targeted cCMV screening of newborns with a failed hearing screen, with standard care for cCMV infection.The incremental costs of identifying 1 cCMV infection, identifying 1 case of cCMV-related hearing loss, and preventing 1 cochlear implant; the incremental reduction in cases of severe to profound hearing loss; and the differences in costs per infant screened by universal or targeted strategies under different assumptions about the effectiveness of antiviral treatment.Among all infants born in the United States, identification of 1 case of cCMV infection by universal screening was estimated to cost $2000 to $10 000; by targeted screening, $566 to $2832. The cost of identifying 1 case of hearing loss due to cCMV was as little as $27 460 by universal screening or $975 by targeted screening. Assuming a modest benefit of antiviral treatment, screening programs were estimated to reduce severe to profound hearing loss by 4.2% to 13% and result in direct costs of $10.86 per newborn screened. However, savings of up to $37.97 per newborn screened were estimated when costs related to functionality were included.Newborn screening for cCMV infection appears to be cost-effective under a wide range of assumptions. Universal screening offers larger net savings and the greatest opportunity to provide directed care. Targeted screening also appears to be cost-effective and requires testing for fewer newborns. These findings suggest that implementation of newborn cCMV screening programs is warranted.
History of Podophyllin
Authors: Ismaël Maatouk
Journal: JAMA Dermatology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
TCT-296 Validation of FFR measurement using a new ultra-thin monorail catheter based system
Authors: Hitoshi Matsuo, Yoshiaki Kawase, Kikuchi Jun, Itta Kawamura, Tetsuo Hirata, Tatsuya Saigusa, Munenori Okubo, Taiji Miyake, Syuichi Okamoto, Yoshihiro Nakatani, Hideaki Ota, Kunihiko Tsuchiya, Junko Honye, Takahiko Suzuki
Journal: Journal of the American College of Cardiology (2015)
TCT-657 Stentless vs. Stented Aortic Valve-in-Valve Implantation: Insights from the Valve-in-Valve International Data Registry (VIVID)
Authors: Alison Duncan, Neil Moat, Arend de Weger, Joerg Kempfert, Holger Eggebrecht, Tony Walton, Farrel Hellig, Ran Kornowski, Konstantinos Spargias, Matheus Simonato dos Santos, Oscar Mendiz, Raj Makkar, Mayra Guerrero, Chet Rihal, Isaac George, Creighton Don, Alessandro Iadanza, Vinayak Bapat, Robert Welsh, Harindra Wijeysundera, Rafael Wolff, Sameer Gafoor, Luis Nombela Franco, Javier Cobiella, Danny Dvir
Journal: Journal of the American College of Cardiology (2016)
Percutaneous transhepatic biliary drainage-assisted, endoscopic ultrasound-guided hepaticoduodenostomy for isolated complete right intrahepatic duct obstruction
Authors: Min Cho, Hoonsub So, Kyoungwon Jung, Jae Lee, Do Park
Journal: Endoscopy (2016)

Endoscopic ultrasound (EUS)-guided biliary drainage has emerged as an alternative modality for an obstructed intrahepatic duct (IHD). However, isolated right IHD obstruction has not been considered suitable for EUS-guided intervention because the right IHD may not be immediately adjacent to the duodenal wall or because the portal vein could be close to the route of approach [1]. We report our experience of percutaneous transhepatic biliary drainage (PTBD)-assisted, EUS-guided hepaticoduodenostomy for isolated complete right IHD obstruction.
TCT-85 Safety and Performance of the EnligHTN Renal Denervation System in Patients with Severe Uncontrolled Hypertension: 12 Month Results from the EnligHTN II Study
Authors: Melvin Lobo, Joseph Montarello, Manish Saxena, Ajay Jain, Darren Walters, Matthew W. Pincus, Stephen G. Worthley
Journal: Journal of the American College of Cardiology (2015)
Enzastaurin in Patients with Non-Hodgkin Lymphomas: A Multicenter, Open-Label, Screening Study.
Authors: Cecily J. Forsyth, David Gomez, Paul Eliadis, Erick Crespo-Solis, Juliana Pereira, Stephanie Roberson, Deborah Anderson, Oday Hamid, Neil V Smith
Journal: Blood (2009)
Chlamydia Psittaci negative MALT Lymphomas of the Ocular Adnexa Are Characterized by Biased Use of the VH4 Family and Evidence for Antigen Selection
Authors: Daxing Zhu, Chen Lossos, Jennifer R Chapman-Fredricks, Julie M Mattews, Offiong F Ikpatt, Phillip Ruiz, Izidore S Lossos
Journal: Blood (2011)
TCT-240 Aspiration Thrombectomy during ST-Elevation Myocardial infarction: An updated Systematic Review and Meta-Analysis of Randomized Controlled Trials- 2015
Authors: Vikas Singh, Abhijit Ghatak, Ghanshyam P. Subash Shantha, Magdalena Murman, Carlos Alfonso, Eduardo de Marchena, William W. O'Neill, Mauricio G. Cohen
Journal: Journal of the American College of Cardiology (2015)
Prognostic value of class III b-tubulin (TUBB3) in operable non-small cell lung cancer (NSCLC) and predictive value for adjuvant cisplatin-based chemotherapy (CT): A validation study on three randomized trials
Authors: T. Reiman, P. Seve, A. Vataire, A. Dunant, R. Rosell, S. Graziano, L. Seymour, R. Pirker, R. Lai
Journal: Journal of Clinical Oncology (2008)

7506 Background: The IALT and JBR.10 randomized trials both demonstrated the survival advantage of adjuvant platinum-based CT for patients with resected NSCLC. We previously showed by immunohistochemistry (IHC) that high TUBB3 expression might correlate with greater benefit from adjuvant vinorelbine/cisplatin CT in an analysis of tumor tissues from 265 patients in the JBR.10 trial. Here, we sought to verify the previous suggestions in the IALT trial. Since some CT regimens in the IALT trial did not include an anti-tubulin agent, we also tested the hypothesis that the value of TUBB3 expression in predicting benefit from CT was specific to anti-tubulin containing regimens. Methods: Tissue microarrays representing 737 patients on the IALT trial were stained for TUBB3. A score was generated based on the intensity and the proportion of positive-staining tumor cells in each case. Patients were classified as having high or low TUBB3 expression based on the median score. Correlations were assessed between TUBB3 and known prognostic factors, disease-free survival (DFS), overall survival (OS) and CT effect through stratified logistic and Cox models. Results: High TUBB3 expression significantly correlated with adenocarcinoma histology (p=0.0001), lymphatic (p=0.03) and vascular invasion (p=0.01), and DFS (HR 1.26, 95% CI 1.01–1.58, p = 0.04), with a similar trend in OS (p=0.12). There was no significant interaction seen between TUBB3 status and treatment assignment in predicting DFS (HR for CT effect in high versus low TUBB3 groups =0.92, p=0.71) or OS (HR=1.01, p=0.98), nor when the analysis was restricted to anti-tubulin containing regimens (DFS: HR=0.90, p=0.71; OS: HR=0.93, p=0.82). Conclusions: High TUBB3 expression is an adverse prognostic factor in IALT, in concordance with prior observations in JBR.10. However, unlike what was suggested in JBR.10, in IALT TUBB3 expression did not correlate with benefit from adjuvant chemotherapy. More insight into the role of TUBB3 will be given at the time of the meeting when the results of IALT together with ANITA and CALGB 9633 trials will be available. No significant financial relationships to disclose.
Eligibility for the Shorter Multidrug-Resistant Tuberculosis Regimen: Ambiguities in the World Health Organization Recommendations
Authors: Francis Varaine, Lorenzo Guglielmetti, Helena Huerga, Maryline Bonnet, Nana Kiria, Joseph K. Sitienei, Michael Rich, Carole D. Mitnick
Journal: American Journal of Respiratory and Critical Care Medicine (2016)
GW27-e0682 Sulforaphane alleviates myocardial ischemia/reperfusion injury by up-regulation of autophagy via AMPK/mTOR pathway
Authors: Li Yunpeng, Shulin Wang, Lu Tang, Xianbao Wang, Linlin Chen, Xudong Song, Lizi Wang, Aihua Chen
Journal: Journal of the American College of Cardiology (2016)
Rituximab Maintenance Therapy after Autologous Stem Cell Transplantation Improves Survival of Patients with Mantle Cell Lymphoma
Authors: Solomon A. Graf, Philip A. Stevenson, Leona A. Holmberg, Brian G. Till, Oliver W. Press, Thomas R. Chauncey, Stephen D. Smith, Mary Philip, Johnnie J. Orozco, Andrei R. Shustov, Damian J. Green, Edward N. Libby, William I. Bensinger, John M. Pagel, David G Maloney, Yi Zhou, Ryan D. Cassaday, Ajay K. Gopal
Journal: Blood (2014)
TCT-236 The role of ADAMTS13 in acute myocardial infarction: cause or consequence?
Authors: Paul F. Teunissen, Otto Kamp, Pieter Willem Kamphuisen, Joost Meijers, Ruben Tijssen, Elise S. Eerenberg, Matthijs F. Jansen, Hans W. Niessen, Niels van Royen
Journal: Journal of the American College of Cardiology (2015)
Hematopoietic stem cell transplantation corrects WIP deficiency
Authors: Hamoud Al-Mousa, Abbas Hawwari, Abdulaziz Al-Ghonaium, Bandar Al-Saud, Hasan Al-Dhekri, Saleh Al-Muhsen, Sahar Elshorbagi, Majed Dasouki, Lina El-Baik, Amal Alseraihy, Mouhab Ayas, Rand Arnaout
Journal: Journal of Allergy and Clinical Immunology (2016)
TCT-263 Relationship Between Therapeutic Effects on Infarct Size in Acute Myocardial Infarction and One-year Outcomes: Patient-Level Analysis of Randomized Clinical Trials
Authors: James Udelson, Harry Selker, Robin Ruthazer, Holger Thiele, Manesh Patel, E. Magnus Ohman, Akiko Maehara, Paul Jenkins, Melissa Nichols, Ori Ben-Yehuda, Gregg W. Stone
Journal: Journal of the American College of Cardiology (2015)
TCT-208 Comparison Of Antithrombotic Regimens For Primary Angioplasty In Patients &gt; 75 Years With ST Elevated Myocardial Infarction: The ESTROFA-MI+75 Study
Authors: Jose M. De la Torre Hernandez, Jose A. Baz, Joan A. Gomez Hospital, Salvatore Brugaletta, Ramon Lopez Palop, Armando Pérez de Prado, Belen Cid, Alejandro Diego-Nieto, Federico Gimeno, Jose Antonio Fernandez Diaz, Juan Sanchis, Fernando Alfonso, Roberto Blanco, Javier Botas Rodriguez, Javier Navarro Cuartero, Jose Moreu, Francisco Bosa, Jose Miguel Vegas, Jaime Elizaga, Antonio L. Arrebola-Moreno, Jose A. Linares, Felipe Hernandez, Leire Andraka, Manuel Jimenez Navarro, Fernando Lozano, Jose R. Rumoroso
Journal: Journal of the American College of Cardiology (2015)
Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with <i>BRAF</i>V600E Mutation
Authors: David S. Hong, Van K. Morris, Badi El Osta, Alexey V. Sorokin, Filip Janku, Siqing Fu, Michael J. Overman, Sarina Piha-Paul, Vivek Subbiah, Bryan Kee, Apostolia M. Tsimberidou, David Fogelman, Jorge Bellido, Imad Shureiqi, Helen Huang, Johnique Atkins, Gabi Tarcic, Nicolas Sommer, Richard Lanman, Funda Meric-Bernstam, Scott Kopetz
Journal: Cancer Discovery (2016)

Abstract In vitro, EGFR inhibition, combined with the BRAF inhibitor vemurafenib, causes synergistic cytotoxicity for BRAFV600E metastatic colorectal cancer, further augmented by irinotecan. The safety and efficacy of vemurafenib, irinotecan, and cetuximab in BRAF-mutated malignancies are not defined. In this 3+3 phase I study, patients with BRAFV600E-advanced solid cancers received cetuximab and irinotecan with escalating doses of vemurafenib. Nineteen patients (18 with metastatic colorectal cancer and 1 with appendiceal cancer) were enrolled. Three patients experienced dose-limiting toxicities. The MTD of vemurafenib was 960 mg twice daily. Six of 17 evaluable patients (35%) achieved a radiographic response by Response Evaluation Criteria in Solid Tumors 1.1 criteria, consistent with in vivo models demonstrating tumor regressions with the triplet regimen. Median progression-free survival was 7.7 months. BRAFV600E circulating cell-free DNA (cfDNA) trends correlated with radiographic changes, and acquired mutations from cfDNA in genes reactivating MAPK signaling were observed at progression. Significance: Vemurafenib, in combination with irinotecan and cetuximab, was well tolerated in patients with refractory, BRAF-mutated metastatic colorectal cancer, and both survival outcomes and response rates exceeded prior reports for vemurafenib and for irinotecan plus cetuximab in BRAFV600E metastatic colorectal cancer. In vivo models demonstrated regressions with the triplet, in contrast with vemurafenib and cetuximab alone. cfDNA predicted radiographic response and identified mutations reactivating the MAPK pathway upon progression. Cancer Discov; 6(12); 1352–65. ©2016 AACR. This article is highlighted in the In This Issue feature, p. 1293